找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Combination Treatment in Autoimmune Diseases; W. B. Harrison,B. A. C. Dijkmans Book 2002 Springer-Verlag Berlin Heidelberg 2002 Autoimmune

[复制链接]
楼主: FETUS
发表于 2025-3-23 11:03:05 | 显示全部楼层
发表于 2025-3-23 17:49:51 | 显示全部楼层
Spondylarthropathies: options for combination therapy of diseases. Patients may have more than one symptom at the same time or at different moments during life. A positive family history is an important hallmark of SpA, and reflects its genetic background.
发表于 2025-3-23 20:24:15 | 显示全部楼层
Christoph G. Schuetz,Michael Schreflale population (6% overall), and an annual prevalence of SSc of 15 cases per 100,000. Data from the UK has previously estimated a much lower prevalence but a comprehensive local study has led to estimates being revised to levels similar to the North American figures [28].
发表于 2025-3-24 01:20:03 | 显示全部楼层
Combination therapies for systemic sclerosisale population (6% overall), and an annual prevalence of SSc of 15 cases per 100,000. Data from the UK has previously estimated a much lower prevalence but a comprehensive local study has led to estimates being revised to levels similar to the North American figures [28].
发表于 2025-3-24 03:08:57 | 显示全部楼层
发表于 2025-3-24 08:56:21 | 显示全部楼层
A Survey of IoT Software Platformsggressive initial therapy. These adagia have influenced in recent times all fields of medicine, from oncology to infectious diseases and also — the topic of the present edition — the “autoimmune diseases”. As an example of the latter, rheumatoid arthritis (RA) demonstrates how the attitude of physicians has been changed.
发表于 2025-3-24 13:18:46 | 显示全部楼层
https://doi.org/10.1007/978-3-319-14139-8ture mortality. Even though methotrexate (MTX) has become a “gold standard” of therapy, its use rarely results in disease remission. The recent introduction of new treatments which offer significant incremental improvements in both efficacy and tolerability argues strongly for utilization of combination therapy.
发表于 2025-3-24 17:15:21 | 显示全部楼层
发表于 2025-3-24 22:32:34 | 显示全部楼层
发表于 2025-3-25 00:16:28 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-26 09:41
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表